Diltiazem + MK-6916 for Healthy Subjects

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Merck Sharp & Dohme LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?The goal of the study is to learn what happens to levels of MK-6916 in a healthy person's body over time. Researchers will compare what happens to MK-6916 in the body when it is given with or without another medicine called diltiazem.

Eligibility Criteria

This trial is for healthy individuals with a BMI between 18 to 32 kg/m^2. The study aims to understand how the body processes MK-6916, both alone and when taken with another drug called diltiazem.

Inclusion Criteria

My BMI is between 18 and 32.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive MK-6916 and diltiazem orally to evaluate pharmacokinetics

8 weeks

Multiple visits for blood sampling

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Participant Groups

The study is testing the effects of multiple doses of Diltiazem on plasma levels of a drug called MK-6916 in healthy participants. It will compare the changes in MK-6916 levels when administered alone versus alongside Diltiazem.

1Treatment groups

Experimental Treatment

Group I: MK-6916 + DiltiazemExperimental Treatment2 Interventions

Participants will receive MK-6916 and diltiazem orally.